FDA Approves Almotriptan to Treat Migraines in Adolescents

Yael Waknine

June 03, 2009

June 3, 2009 — On April 30, the FDA approved an expanded indication for almotriptan malate (Axert tablets, Ortho-McNeil Janssen Pharmaceuticals) for the acute treatment of migraine headache in adolescents aged 12 to 17 years. Almotriptan previously was approved for use in adults only.

The approval was based on data from a double-blind, placebo-controlled, randomized study of 528 adolescents having at least a 1-year history of migraine attacks with or without aura and usually lasting 4 hours or more.

Results showed that the percentage of patients achieving a pain relief response (mild or no pain) 2 hours after treatment was statistically significantly greater with almotriptan 6.25 mg relative to placebo (71.8% vs 55.3%; P < .001); an increased dose of 12.5 mg almotriptan did not confer additional benefit (response rate, 72.9%).

The efficacy of almotriptan on migraine-associated symptoms was not established in the study, which showed a similar prevalence of nausea, photophobia, and phonophobia at 2 hours postdose across treatment and placebo groups.

Adverse events reported with almotriptan occurred in less than 5% of patients and most commonly included dizziness, nausea, vomiting, and headache.

As with adults, the recommended dose of almotriptan in adolescents is 6.25 or 12.5 mg. A second dose may be administered after 2 hours if headache returns, not to exceed a maximum daily dose of 25 mg.

Reduced doses of 6.25 mg should be used in patients with hepatic or severe renal impairment (maximum daily dose, 12.5 mg).

Because of the potential for serotonin syndrome, caution is advised with use of almotriptan in patients receiving concomitant treatment with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. Symptoms of serotonin syndrome may include autonomic instability, neuromuscular aberrations, and/or gastrointestinal effects.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.